Investors cool on new bavi data in NSCLC but Peregrine eyes Phase III
This article was originally published in Scrip
Executive Summary
Investors were unimpressed with updated Phase II results for Peregrine Pharmaceuticals' bavituximab as a second-line therapy for patients with non-small cell lung cancer (NSCLC) following an earlier report of data discrepancies from the trial.